Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif Faron commences enrolment in Phase II trial of traumakine to treat MOF in RAAA http://www.drugdevelopment-technology.com/news/newsfaron-commences-enrollment-in-phase-ii-trial-of-traumakine-to-treat-mof-in-raaa-5744523 http://www.drugdevelopment-technology.com/news/newsfaron-commences-enrollment-in-phase-ii-trial-of-traumakine-to-treat-mof-in-raaa-5744523 Finland-based clinical stage biopharmaceutical firm Faron Pharmaceuticals has commenced enrolment in the Phase II INFORAAA clinical trial of traumakine (FP-1201-lyo) to treat patients with multi-organ failure (MOF) in ruptured abdominal aorta aneurys… Tue, 21 Feb 2017 00:00:00 GMT Chi-Med begins Phase II trial of savolitinib to treat PSC in China http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-ii-trial-of-savolitinib-to-treat-psc-in-china-5744885 http://www.drugdevelopment-technology.com/news/newschi-med-begins-phase-ii-trial-of-savolitinib-to-treat-psc-in-china-5744885 Biopharmaceutical firm Hutchison China MediTech (Chi-Med) has begun a Phase II clinical trial of savolitinib for the treatment of locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. Tue, 21 Feb 2017 00:00:00 GMT Celgene reports positive top-line results from Phase III trial of ozanimod to treat RMS http://www.drugdevelopment-technology.com/news/newscelgene-reports-positive-top-line-results-from-phase-iii-trial-of-ozanimod-to-treat-rms-5744498 http://www.drugdevelopment-technology.com/news/newscelgene-reports-positive-top-line-results-from-phase-iii-trial-of-ozanimod-to-treat-rms-5744498 US-based biotechnology firm Celgene has reported positive top-line results from the Phase III clinical trial (SUNBEAM) of oral ozanimod for the treatment of patients with relapsing multiple sclerosis (RMS). Tue, 21 Feb 2017 00:00:00 GMT Malvern to Host Webinar on Characterisation and Optimisation of Particle Size and Shape of Metal Powders http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/presswebinar-characterisation-optimisation-particle-size-shape-metal-powders.html http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/presswebinar-characterisation-optimisation-particle-size-shape-metal-powders.html Efficiency of the production process of powder bed additives is reliant on packing density and flow behaviour of metal powders involved. Mon, 20 Feb 2017 14:58:00 GMT Optimising Development Resources for Efficient Product Development http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/development-resources-efficient/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/development-resources-efficient/ Development departments suffer from a shortage of resources and are often overburdened with administration tasks. Mon, 20 Feb 2017 10:57:00 GMT University of Liverpool and AKL collaborate to evaluate APPA for osteoarthritis http://www.drugdevelopment-technology.com/news/newsuniversity-of-liverpool-and-akl-collaborate-to-evaluate-appa-for-osteoarthritis-5743748 http://www.drugdevelopment-technology.com/news/newsuniversity-of-liverpool-and-akl-collaborate-to-evaluate-appa-for-osteoarthritis-5743748 The University of Liverpool has collaborated with pharmaceutical firm AKL Research and Development to evaluate a new drug 'APPA' for the treatment of osteoarthritis. Mon, 20 Feb 2017 00:00:00 GMT AstraZeneca announces positive results from Phase III trial of Lynparza for breast cancer http://www.drugdevelopment-technology.com/news/newsastrazeneca-announces-positive-results-from-phase-iii-trial-of-lynparza-for-breast-cancer-5744013 http://www.drugdevelopment-technology.com/news/newsastrazeneca-announces-positive-results-from-phase-iii-trial-of-lynparza-for-breast-cancer-5744013 Biopharmaceutical firm AstraZeneca has announced positive results from its Phase III clinical trial (OlympiAD) of Lynparza (olaparib) to treat patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Mon, 20 Feb 2017 00:00:00 GMT Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma http://www.drugdevelopment-technology.com/news/newstracon-commences-dosing-in-phase-iii-trial-of-trc105-to-treat-angiosarcoma-5742999 http://www.drugdevelopment-technology.com/news/newstracon-commences-dosing-in-phase-iii-trial-of-trc105-to-treat-angiosarcoma-5742999 US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma. Mon, 20 Feb 2017 00:00:00 GMT Malvern to Unveil New Protein Stability Analysis Device http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/pressmalvern-unveil-protein-stability-analysis-device.html http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/pressmalvern-unveil-protein-stability-analysis-device.html Malvern has announced it will be unveiling its new protein stability characterisation product for regulated environments MicroCal PEAQ-DSC in an upcoming webinar. Fri, 17 Feb 2017 10:24:00 GMT Deals this week: Aldeyra Therapeutics, Oncology Venture Sweden, Treos Bio http://www.drugdevelopment-technology.com/news/newsdeals-this-week-aldeyra-therapeutics-inc-oncology-venture-sweden-ab-treos-bio-ltd-5741806 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-aldeyra-therapeutics-inc-oncology-venture-sweden-ab-treos-bio-ltd-5741806 US-based biotechnology company Aldeyra Therapeutics has announced a public offering of shares of its common stock to raise funds required primarily for the continued development of its lead compound, ADX-102, and other product candidates. Fri, 17 Feb 2017 00:00:00 GMT M&As this week: Inhalation Sciences, Quotient Clinical http://www.drugdevelopment-technology.com/news/newsmas-this-week-inhalation-sciences-quotient-clinical-5741746 http://www.drugdevelopment-technology.com/news/newsmas-this-week-inhalation-sciences-quotient-clinical-5741746 Swedish drug development services provider Inhalation Sciences Sweden has been acquired by a consortium comprising Per Gerde, Fredrik Sjovall, and Rasunda Forvaltning. Fri, 17 Feb 2017 00:00:00 GMT Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals. Fri, 17 Feb 2017 00:00:00 GMT Theratechnologies reports comparative PK Data on IM and IV administration of ibalizumab in HIV patients http://www.drugdevelopment-technology.com/news/newstheratechnologies-reports-positive-data-from-tmb-121-trial-of-ibalizumab-in-mdr-hiv-5741777 http://www.drugdevelopment-technology.com/news/newstheratechnologies-reports-positive-data-from-tmb-121-trial-of-ibalizumab-in-mdr-hiv-5741777 Pharmaceutical firm Theratechnologies has announced the pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the intramuscular (IM) with the intravenous (IV) administration of ibalizumab. Fri, 17 Feb 2017 00:00:00 GMT Ardelyx reports positive results from Phase III trial of tenapanor for hyperphosphatemia http://www.drugdevelopment-technology.com/news/newsardelyx-reports-positive-results-from-phase-iii-trial-of-tenapanor-for-hyperphosphatemia-5741794 http://www.drugdevelopment-technology.com/news/newsardelyx-reports-positive-results-from-phase-iii-trial-of-tenapanor-for-hyperphosphatemia-5741794 Ardelyx has reported positive results from the Phase III clinical trial of tenapanor to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. Fri, 17 Feb 2017 00:00:00 GMT Symbicort (budesonide and formoterol) for the Treatment of Asthma http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZe… Fri, 17 Feb 2017 00:00:00 GMT ePAT Automated Lab Reactor Optimised for 24/7 Data Capture http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ Systag Systems presents ePAT, a cost-effective device for automation in the laboratory. Thu, 16 Feb 2017 16:57:00 GMT GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/gpcsec-polymer-dd/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/gpcsec-polymer-dd/ Inkjet printing of polymer solutions is an area of interest for depositing precise, high-throughput patterns of functional polymer. The applications of the polymer patterns include OLEDs, organic cir... Thu, 16 Feb 2017 15:00:00 GMT Sanofi initiates Phase II trial of GZ/SAR402671 to treat Parkinson’s Disease with GBA gene http://www.drugdevelopment-technology.com/news/newssanofi-initiates-phase-ii-trial-of-gzsar402671-to-treat-parkinsons-with-gba-gene-5740872 http://www.drugdevelopment-technology.com/news/newssanofi-initiates-phase-ii-trial-of-gzsar402671-to-treat-parkinsons-with-gba-gene-5740872 Sanofi's specialist care global business unit Sanofi Genzyme has initiated a Phase II trial of an investigational oral therapy GZ/SAR402671 to treat patients with Parkinson’s disease, who carry a single copy mutation of the glucocerebrosidase (GBA) g… Thu, 16 Feb 2017 00:00:00 GMT Berg begins Phase I/II trial of BPM 31510-IV in patients with glioblastoma multiforme http://www.drugdevelopment-technology.com/news/newsberg-begins-phase-iii-trial-of-bpm-31510-iv-in-patients-with-glioblastoma-multiforme-5741150 http://www.drugdevelopment-technology.com/news/newsberg-begins-phase-iii-trial-of-bpm-31510-iv-in-patients-with-glioblastoma-multiforme-5741150 Biopharmaceutical firm Berg has begun a Phase I/II monotherapy clinical trial of its drug candidate BPM 31510-IV to treat patients with glioblastoma multiforme (GBM). Thu, 16 Feb 2017 00:00:00 GMT Merck reports positive results from Phase III trial of doravirine to treat HIV-1 http://www.drugdevelopment-technology.com/news/newsmerck-reports-positive-results-from-phase-iii-trial-of-doravirine-to-treat-hiv-1-5740855 http://www.drugdevelopment-technology.com/news/newsmerck-reports-positive-results-from-phase-iii-trial-of-doravirine-to-treat-hiv-1-5740855 Merck has reported positive results from a pivotal Phase III clinical trial of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection. Thu, 16 Feb 2017 00:00:00 GMT